How to treat methytlith-positive late-stage solid tumor? The effectiveness of the new T-cell therapy TC-210 is significant.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
TCR2, a !---- immunotherapy company that is developing a range of new T-cell therapies for cancer patients, is currently in phase I/II clinical phase to treat methlopathy-positive non-small cell lung cancer (NSCLC), ovarian cancer, pleural/peritoneal lylthyosome and bile duct cancer.TCR2 announced today that in Phase I/II clinical trials, all five patients showed tumor abating after treatment with TC-210, and only one patient showed non-hematological toxicity associated with TC-210, free of neurotoxicity. Dr. Garry Menzel, President and CEO ofTCR2, said, "We are pleased to see the clinical benefits of TC-210 in patients with advanced solid tumors.patients with solid tumors have few treatment options, and methlitoidoid-positive patients represent unmet medical needs."mesothelin is a cell surface glycoprotein with a molecular weight of 40kDa, highly expressed in a variety of tumor tissues, but also in the normal pleural, heart bags and peritoneal interleal cells.mesothelin is also an early biomarker of pancreatic cancer..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
